Evidence-Based Recommendations for Nurse Monitoring and Management of Immunotherapy-Induced Cytokine Release Syndrome: A Systematic Review from the Children's Oncology Group.
Emily K BrowneEmily DautMonica HenteKelly TurnerKatherine WatersElizabeth A DuffyPublished in: Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses (2021)
Children with B-precursor acute lymphoblastic leukemia and B-cell lymphoma, particularly those with relapsed or refractory disease, are increasingly enrolled on phase II and phase III clinical trials studying immunotherapies. These therapeutic agents may be associated with a high risk of cytokine release syndrome (CRS), and nurses lack standardized guidelines for monitoring and managing patients with CRS. Six studies and one clinical practice guideline were included in this systematic review that examined the evidence of CRS following administration of chimeric antigen receptor T-cell therapy or the bi-specific T-cell engager antibody, blinatumomab. Six nursing practice recommendations (five strong, one weak) were developed based on low or very low-quality evidence: three reflect preinfusion monitoring, one focuses on monitoring during and postinfusion, and three pertain to the nurse's role in CRS management.
Keyphrases
- acute lymphoblastic leukemia
- phase ii
- clinical trial
- phase iii
- cell therapy
- open label
- systematic review
- primary care
- healthcare
- young adults
- diffuse large b cell lymphoma
- mental health
- allogeneic hematopoietic stem cell transplantation
- palliative care
- mesenchymal stem cells
- acute myeloid leukemia
- stem cells
- case report
- placebo controlled
- multiple myeloma
- high glucose
- diabetic rats
- meta analyses
- endothelial cells
- oxidative stress
- study protocol
- stress induced